Drugs / 131I-TM601
131I-TM601
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT00683761 | Aug 2008 → Feb 2010 | astrocytoma (excluding glioblastoma), glioblastoma, oligodendroglioma | TransMolecular | Unknown | No outcome recorded |
| Phase 1/2 | NCT00040573 | Jun 2002 → Aug 2003 | brain neoplasm, glioma | TransMolecular | Completed | No outcome recorded |
| Phase 1/2 | NCT00733798 | — | metastatic melanoma | TransMolecular | Terminated | No outcome recorded Stop: Business |
| Phase 21 trial | ||||||
| Phase 2 | NCT00114309 | Nov 2004 → Mar 2009 | anaplastic astrocytoma, gliosarcoma, oligoastrocytoma | TransMolecular | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 131I-TM-601 | “131I-TM601, in solution, delivered intracavitarily following surgical resection 3 weekly administrations, 0.8 mg TM601 and 40mCi 131Iodine, per dose.” NCT00114309 ↗5“Nonbound 131I-TM-601 was eliminated by 48 h after injection with the remaining radiolabeled peptide bound to tumor for at least 6-8 d.” PMID 15809479 ↗ Apr 2005 |
| Known as | iodine-131-TM-601 | “Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma.” PMID 16877732 ↗ Aug 2006 |
| Known as | TM-601 | “TM-601, a 36-amino-acid peptide, selectively binds to glioma cells but not normal brain parenchyma.” PMID 15809479 ↗ Apr 2005 |
| Modality | Peptide | “TM-601, a 36-amino-acid peptide, selectively binds to glioma cells but not normal brain parenchyma.” PMID 15809479 ↗ Apr 2005 |
| Route | Other | “ventricular access device placement into the tumor cavity for administration of 131I-TM-601.” NCT00040573 ↗ |